About the Global Burden of Disease Study

The Global Burden of Disease Study (GBD), coordinated by the Institute for Health Metrics and Evaluation (IHME), synthesizes a large number of input sources to estimate mortality, causes of death and illness, and burden attributable to risk factors. The GBD estimation process is based on identifying multiple relevant data sources for each disease or injury, including censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Each of these types of data is identified from a systematic review of published studies, searches of government and international organization websites, published reports, primary data sources such as the Demographic and Health Surveys, and contributions of datasets by GBD collaborators. Each obtained data source is given a unique identifier by a team of librarians and included in the Global Health Data Exchange (GHDx). The GHDx makes publicly available the metadata for each source included in GBD, as well as the data, where allowed by the data provider. For most diseases and injuries, processed data are modeled using standardized tools to generate estimates of each quantity of interest by age, sex, location, and year. The GBD estimation methods have been described in detail elsewhere. See also: https://www.thelancet.com/gbd. For terms and conditions of use, please visit http://www.healthdata.org/about/terms-and-conditions. For any usage that falls outside of these license restrictions, please contact IHME Client Services at services@healthdata.org.

All data should be interpreted with caution. Comparisons, especially between countries, should be avoided due to underreporting, differences in surveillance system structures, varying case definitions between countries.

Models of dengue burden are not run for locations where these metrics are assumed to be 0, as listed below:

* Non-fatal metrics such as incidence: Central Europe, Eastern Europe, and Central Asia, Central Asia, Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan, Central Europe, Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Eastern Europe, Belarus, Estonia, Latvia, Lithuania, Moldova, Russian Federation, Ukraine, New Zealand, Japan, South Korea, Canada, Greenland, Chile, Uruguay, Western Europe, Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, United Kingdom, Bermuda, Algeria, Bahrain, Iran, Iraq, Libya, Morocco, Qatar, Tunisia, Turkey, United Arab Emirates, North Korea, Guam, Botswana, Swaziland, Lesotho, Namibia, South Africa, and any subnational location with the listed locations.

* Fatal metrics such as mortality: Central Europe, Eastern Europe, and Central Asia, Central Asia, Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan, Central Europe, Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Eastern Europe, Belarus, Estonia, Latvia, Lithuania, Moldova, Russian Federation, Ukraine, New Zealand, Canada, Greenland, Chile, Uruguay, Andorra, Austria, Belgium, Cyprus, Denmark, Finland, Germany, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Sweden, Switzerland, United Kingdom, Bermuda, Algeria, Iran, Iraq, Libya, Morocco, Tunisia, Turkey, United Arab Emirates, North Korea, Botswana, Swaziland, Lesotho, Namibia, South Africa, and any subnational location with the listed locations.

VV-MEDMAT-112646 December 2024